Nephros Inc. (NEPH) insider have most recently took part in a trading activity. On Dec 4, 2017 Astor Andrew, CFO bought 18,333 shares having total worth of $9,167 at the price of $0.5 per share, following the transaction a total of 215,042 shares owned by Astor Andrew. Before this latest buy, Astor Andrew purchased NEPH at 2 other times during the past twelve months, for a total investment of $7,900 at an average of $0.27 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 9 times by insiders. an employee of the company was the buyer in 9 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Nephros Inc. (NEPH) traded down 0.4% on Dec 4, 2017, hitting $0.49. 92,946 shares of the company’s stock traded hands. Nephros Inc. has a 52 week low of $0.21 and a 52 week high of $0.6. The company’s market cap is $0 million.
Nephros, Inc. was incorporated under the laws of the State of Delaware on April 3, 1997. The Company is engaged in the development of hemodiafiltration, or HDF, products and technologies for treating patients with End Stage Renal Disease, or ESRD. It has three products in various stages of development in the HDF modality to deliver improved therapy to ESRD patients: OLpur MDHDF filter series, OLpur H2H and OLpur NS2000 system. OLpur MD190 and MD220 constitute the Company’s dialyzer cartridge series that incorporates the patented MDF process and is designed for use with existing HDF platforms currently prevalent in its Target European Market and Japan. Its MDHDF filter series incorporates a unique blood-flow architecture that enhances toxin removal with essentially no cost increase over existing devices currently used for HDF therapy. OLpur HD190 is its high-flux dialyzer cartridge, designed for use with either hemodialysis or hemodiafiltration machines. The OLpur HD190 incorporates the same materials as its OLpur MD190, but lacks its proprietary mid-dilution architecture. OLpur H2H is the Company’s add-on module that converts the most common types of hemodialysis machines – that is, those with volumetric ultrafiltration control – into HDF-capable machines allowing them to use its OLpur MDHDF filter. OLpur NS2000 is the Company’s standalone HDF machine and associated filter technology, which is in the development stage. The OLpur NS2000 would use a basic HDF platform which would incorporate its H 2 H technology including its proprietary substitution fluid systems. The Company has also designed and developed proprietary substitution fluid filter cartridges for use with the OLpur NS2000, which have been subjected to pre-manufacturing testing. OLpur and H2H are among the Company’s trademarks for which U.S. registrations are pending. It competes with other suppliers of ESRD therapies, supplies and services. These suppliers include Fresenius Medical Care AG, and Gambro AB. At present, Fresenius Medical Care AG and Gambro AB also manufacture HDF machines. Its competitors in the sale of hemodialysis products include Gambro AB, Baxter International Inc., Asahi Kasei Medical Co. Ltd., Bellco S.p.A., a subsidiary of the Sorin group, B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation and Toray Medical Co., Ltd. The research and development, manufacturing, promotion, marketing and distribution of the Company’s ESRD therapy products in the United States, its Target European Market and other regions of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and analogous agencies.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018